Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND-340 in Post-operative Analgesia for TKA
NCT04515953Phase 1Suspended
- Sponsor
- Nang Kuang Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of bupivacaine hydrochloride 0.75% injection in postoperative pain (2 arms), sponsored by Nang Kuang Pharmaceutical Co., Ltd. Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 up to 3 months, Cmax up to 164 hours and 2 more. Started Oct 2020; status: suspended.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04515953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04515953.